A recent study (JL Slaughter et al. J Pediatric 2016l 174: 63-70) shows a high rate of acid blockers in neonatal intensive care units. This study retrospectively analyzed the Pediatric Health Information System database (PHIS) from 2006-2013.
- Of 122,0002 infants: 23.8% received either a histamine-2-receptor antagonist (H2RA) or proton pump inhibitor (PPI).
- 19.0% had received an H2RA
- 10.5% had received a PPI
My take (borrowed from authors): “despite limited evidence and increasing safety concerns, H2RAs/PPIs are frequently prescribed to extremely preterm neonates…Our findings support the need for innovative studies.” Wouldn’t it be nice if there was proof of efficacy in this population?